RECOVERY & TISSUE REPAIR / COMPARE
Four Peptides, Side by Side
Where the four repair peptides converge, where they diverge, and — most importantly — how far the evidence behind each one actually reaches.
The short version
This page lines up BPC-157, TB-500, GHK-Cu, and KPV on the dimensions that matter most when reading about research peptides: what kind of molecule each one is, where it has been studied most, how strong that evidence is, how it was given in studies, its regulatory standing, and its single biggest caution. The short version is this: all four are studied in the context of recovery and tissue repair, but they are at very different stages of evidence. GHK-Cu has the most human (mostly topical) data. BPC-157 has the deepest animal record with three tiny human pilots. TB-500's evidence largely belongs to a bigger parent protein. KPV has no human trials at all. None is an approved medicine, and no human dose is presented here.
The comparison matrix
| Dimension | BPC-157 | TB-500 | GHK-Cu | KPV |
|---|---|---|---|---|
| Peptide class | Stable gastric pentadecapeptide (15 aa) | Synthetic actin-binding fragment of thymosin beta-4 (7 aa) | Copper-binding tripeptide / copper tripeptide-1 (3 aa) | Melanocortin-derived anti-inflammatory tripeptide (3 aa) |
| Most-studied in | Tendon, gut, muscle, nerve repair | Actin biology, cell migration, angiogenesis | Skin regeneration and matrix synthesis | Gut inflammation (colitis) |
| Evidence base (model) | Mostly rat; 3 small human pilots [2] | Mostly full-length Tβ4 (animal + 1 human Phase 1) [6][9] | In vitro + small human topical trials [16] | In vitro + mouse only; no human trials [20] |
| Administration studied | IM, intragastric, drinking water, IV pilot [3][5] | IV (full-length Tβ4), IP in animals [7][9] | Topical, ex vivo skin penetration [13][17] | Oral / PepT1-targeted nanoparticle delivery in mice [19][20] |
| Regulatory / WADA status | Not approved; WADA S0 prohibited | Not approved; WADA-prohibited | Cosmetic ingredient (topical); systemic unapproved | Not approved; not specifically WADA-listed |
| Key caution | Single-lab, preclinical-heavy record [2] | Fragment vs full-protein identity gap [6][8] | Poor skin permeability; pigmentation risk [13] | Entirely preclinical; no human PK [20] |
Peptide class
The four span a wide size range. BPC-157 is the largest at fifteen amino acids — a stable gastric pentadecapeptide. TB-500 is a seven-amino-acid fragment carrying the actin-binding motif of the much larger thymosin beta-4 protein. GHK-Cu and KPV are both tripeptides (three amino acids), but they differ sharply in character: GHK-Cu is a copper carrier drawn from the collagen sequence, while KPV is the anti-inflammatory C-terminal tail of the hormone alpha-MSH [22].
Most-studied in
Each peptide has a home territory in the research literature. BPC-157's animal record is the broadest, spanning tendon, gut, muscle, and nerve [5]. TB-500's research centers on actin biology and the cell migration and angiogenesis that follow from it [8]. GHK-Cu is overwhelmingly a skin-and-matrix story — collagen, elastin, and the dermal environment [16]. KPV is studied almost entirely in models of gut inflammation, particularly chemically induced colitis in mice [20].
Evidence base (model)
This is where the four genuinely separate. GHK-Cu has the most human data, but it is mostly topical and small-scale, plus one 45-patient combination hair-loss trial [15][16]. BPC-157 has a deep, decades-long animal record and three small uncontrolled human pilots [2]. TB-500 is the trickiest read: its strongest human data — a Phase 1 IV safety study in 40 volunteers — used full-length thymosin beta-4, not the marketed fragment [6][9]. KPV has the least human footing of all: no published human clinical trials, only cell-culture and mouse work [20].
Administration studied
Routes reflect the research questions being asked. BPC-157 has been studied intramuscularly, intragastrically, in drinking water, and in a tiny intravenous human safety pilot [3][5]. TB-500 / Tβ4 work used intravenous dosing in the human Phase 1 study and intraperitoneal dosing in animals [7][9]. GHK-Cu is studied topically, with ex vivo skin-penetration measurements quantifying how much copper crosses the skin [13][17]. KPV's recent work is dominated by oral and PepT1-targeted nanoparticle delivery in mice, because the free tripeptide is fragile [19][20].
Regulatory and WADA status
None of the four is an FDA- or EMA-approved medicine for systemic use. BPC-157 and TB-500 are both explicitly prohibited in sport by WADA — BPC-157 under the S0 non-approved-substances category [6]. GHK-Cu is unusual in this group: topical copper tripeptide-1 is a legal, widely sold cosmetic ingredient, while injectable or systemic GHK-Cu is unapproved and research-only [13]. KPV is not specifically named on the WADA Prohibited List, but as a non-approved peptide it should be treated cautiously in any sport context.
Key caution
Each peptide carries a defining caveat worth stating plainly. For BPC-157 it is that the broad, internally consistent signal comes mostly from one lab's rodents, with only three tiny human pilots [2]. For TB-500 it is the identity gap — the marketed fragment is not the molecule behind most of the efficacy data, and the parent protein carries a theoretical tumor-angiogenesis signal [6][8]. For GHK-Cu it is poor skin permeability and a documented hyperpigmentation risk [13]. For KPV it is that the entire literature is preclinical, with no validated human pharmacokinetics [20]. Taken together, the lesson is consistent: promising mechanisms in animals, uneven and often early evidence in people.